The Food and Drug Administration granted accelerated approval on Wednesday for a new drug developed by researchers at the ...

The research highlights the role of immune checkpoint inhibitors, drugs that enhance the body's ability to fight tumors.

The partners said a TROP2-targeting antibody drug conjugate succeeded in a late-stage trial, paving the way for potential ...

At a recent CURE Educated Patient® Lung Cancer Summit, held in tandem with the 2025 PER® New York Lung Cancer Symposium, Dr. Lanyi Nora Chen, sat down for a live interview with CURE, in which, she ...

A 75-year-old man with non-small cell lung cancer shows radiologic enlargement after neoadjuvant therapy; however, ...

Lung cancer is no longer solely a smoker's disease, with air pollution emerging as a significant risk factor affecting ...

Targeted therapies, guided by molecular testing, offer significant benefits, including fewer side effects and personalization ...

Future SCLC treatment may involve combining T-cell engagers with immune checkpoint inhibitors to enhance patient outcomes.

The accelerated FDA approval of Bayer's Hyrnuo covers treatment of advanced cases of non-small cell lung cancer with HER2 ...

November is Lung Cancer Awareness Month, and the Mississippi State Department of Health (MSDH) is encouraging smokers and ...

Low screening rates and the stigma of smoking mean many patients are diagnosed too late to benefit from treatments, according ...

Diarrhea is not a common direct symptom of lung cancer itself, but it can occur in advanced stages due to the cancer’s impact on the immune system. The primary reason lung cancer patients experience ...